Trial Profile
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Hypercholesterolaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 10 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Aug 2015 Esperion Therapeutics expects to hold an end-of-phase II meeting with the US FDA for bempedoic acid in the first half of August 2015, according to a media release.
- 28 Jul 2015 Primary endpoint has been met. (Percent change in calculated LDL-cholesterol (LDL-C)) according to an Esperion Therapeutics media release.